Baseline characteristics of the 97 patients with Crohn's disease and symptomatic small bowel stricture
| Characteristics | n, frequency (%) or median (IQR) |
|---|---|
| Male | 44 (45) |
| Age (years) | 36 (29–46) |
| Time since diagnosis (years) | 8.8 (3.4–14.9) |
| Crohn’s disease phenotype at inclusion (Montreal classification)* | |
| L1 (ileal disease) | 58 (60) |
| L2 (colonic disease) | 3 (3) |
| L3 (ileocolonic disease) | 36 (37) |
| B2 (stricturing disease) | 97 (100) |
| p† | 19 (20) |
| Previous intestinal resection | 43 (44) |
| Previous treatment with infliximab | 7 (7) |
| Smoking history | |
| Never | 38 (39) |
| Current | 42 (43) |
| Previous | 17 (18) |
| Concomitant drug(s) at the time of inclusion | |
| 5-aminosalicylates | 15 (15) |
| Budesonide ≥9 mg/day | 22 (23) |
| Steroids ≥20 mg/day | 20 (21) |
| Thiopurines | 40 (41) |
| Methotrexate | 1 (1) |
| No treatment | 21 (22) |
| Clinical activity (Crohn's Disease Activity Index >150) | 58 (60) |
| C reactive protein (mg/dL) (n=92) | 5.0 (2.0–11.8) |
| Description of the obstructive symptoms | |
| Onset delay (weeks) | 16 (6–48) |
| Evaluation of obstructive score on a seven-grade score‡ | |
| 3 | 7 (7) |
| 4 | 31 (32) |
| 5 | 37 (38) |
| 6 | 22 (23) |
*Satsangi et al.2
†Perianal disease modifier added to B when concomitant perianal disease is present.
‡See table 1 for descriptions of the grades.